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Abstract 
Although exact causes of Parkinson disease (PD) remain enigmatic, mitochondrial dysfunction is 
increasingly appreciated as a key determinant of dopaminergic neuron susceptibility in both 
familial and sporadic PD. Two genes associated with recessive, early-onset PD encode the 
ubiquitin (Ub) kinase PINK1 and the E3 Ub ligase PRKN/PARK2/Parkin, which together 
orchestrate a protective mitochondrial quality control (mitoQC) pathway. Upon stress, both 
enzymes cooperatively identify and decorate damaged mitochondria with phosphorylated poly-
Ub (p-S65-Ub) chains. This specific label is subsequently recognized by autophagy receptors 
that further facilitate mitochondrial degradation in lysosomes (mitophagy). Here, we analyzed 
human post-mortem brain specimens and identified distinct pools of p-S65-Ub-positive 
structures that partially colocalized with markers of mitochondria, autophagy, lysosomes and/or 
granulovacuolar degeneration bodies. We further quantified levels and distribution of the 
‘mitophagy tag’ in 2 large cohorts of brain samples from normal aging and Lewy body disease 
(LBD) cases using unbiased digital pathology. Somatic p-S65-Ub structures independently 
increased with age and disease in distinct brain regions and enhanced levels in LBD brain were 
age- and Braak tangle stage-dependent. Additionally, we observed significant correlations of p-
S65-Ub with LBs and neurofibrillary tangle levels in disease. The degree of co-existing p-S65-
Ub signals and pathological PD hallmarks increased in the pre-mature stage, but decreased in the 
late stage of LB or tangle aggregation. Altogether, our study provides further evidence for a 
potential pathogenic overlap among different forms of PD and suggests that p-S65-Ub can serve 
as a biomarker for mitochondrial damage in aging and disease. 
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Introduction 
Parkinson disease (PD) is the second most common neurodegenerative disease, with aging being 
the most important risk factor [1]. Incidence rates increase with age from approximately 1% in 
the 60s to 4-5% in the 80s [2]. Clinically, PD is characterized by motor symptoms [3] arising 
from the selective loss of dopamine neurons in the substantia nigra (SN) that project to the 
caudate nucleus and putamen [4]. During the disease course, neuronal degeneration also affects 
other brain regions (e.g., olfactory bulb, nucleus basalis of Meynert [nbM], hippocampus, 
amygdala and neocortex), contributing to comorbid non-motor symptoms. Neuropathologically, 
PD is characterized by the presence of fibrillar SNCA/alpha-synuclein aggregates in neuronal 
somata (Lewy bodies; LBs) and processes (Lewy neurites) [5]. Yet, there is considerable 
phenotypic overlap in a clinicopathological continuum of neuropathologically diagnosed LB 
disease (LBD) cases. The clinical spectrum includes pure PD, PD with dementia (PDD) and 
dementia with Lewy bodies (DLB), and the clinical manifestations predominantly depend on the 
anatomical distribution and load of SNCA pathology [6, 7]. In addition, hyperphosphorylated 
MAPT (microtubule associated protein tau; p-MAPT) and resulting neurofibrillary tangles have 
been observed in several brain areas in PD [8]. Both SNCA and MAPT pathologies may act 
synergistically [9], and variants in genes encoding these 2 proteins are the most significant 
genetic PD risk factors known [10].  
Familial forms of PD have been identified in 5-10% of all patients and have been 
attributed to mutations in more than 20 different disease genes and risk factors [11]. Loss-of-
function mutations in PINK1 (PTEN induced putative kinase 1) and PRKN/PARK2 (parkin RBR 
E3 ubiquitin protein ligase) are the most common causes of hereditary early-onset PD (EOPD; 
defined as an age of onset ≤50 yr) [12]. While the encoded enzymes PINK1 and PRKN are 
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broadly cytoprotective, they appear particularly critical for survival of dopamine neurons [13, 
14]. Though exact disease mechanisms remain unknown, accumulating evidence suggests that 
neuroprotection may occur through PINK1-PRKN-mediated mitochondrial quality control 
(mitoQC). This multifaceted pathway is thought to regulate various aspects of mitochondrial 
health and function including but not limited to antioxidant mechanisms, stress response 
morphology, transport, biogenesis, and degradation [15, 16]. Upon mitochondrial stress, the 
ubiquitin (Ub) kinase PINK1 accumulates on the mitochondrial surface and phosphorylates 
serine 65 of Ub (p-S65-Ub) and of PRKN in order to activate and locally recruit this E3 Ub 
ligase from the cytosol [17]. Both enzymes then jointly amplify the formation of phosphorylated 
poly-Ub chains on mitochondria. This specific label is decoded by autophagy receptors that bind 
members of the MAP1LC3/LC3 (microtubule associated protein 1 light chain 3) family on 
phagophores, the precursors to autophagosomes, and thereby direct damaged mitochondria to 
lysosomes for clearance (mitophagy) [18, 19].  
Mitophagy can be impaired at multiple steps, but the outcomes with respect to p-S65-Ub 
levels may differ. Not only stress and PINK1-PRKN, but also autophagic and lysosomal 
capacities play critical roles for the effective turnover of damaged mitochondria. Complete loss 
of PINK1 or PRKN causes EOPD and prevents the induction or flux of mitophagy through 
absent/reduced levels of the p-S65-Ub degradation label. In addition to EOPD, reduced activities 
of either enzyme may also contribute to later onset PD or at least modify rates of progression and 
clinical phenotypes [20, 21]. Yet, in the presence of functional PINK1-PRKN, enhanced 
mitochondrial dysfunctions as well as defects in autophagic/lysosomal clearance, both well-
documented pathogenic features of PD [22, 23], may result in detectable accumulation of this 
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transient ‘mitophagy tag’. Regardless of this difference, mitoQC is emerging as a candidate for a 
potential great pathogenic overlap between different forms of familial and sporadic PD [24].  
While mitoQC has been intensely investigated in cell lines, the physiological significance 
in neurons, in vivo and the specific contribution of its failure to the pathogenesis of PD remain 
uncertain. Here, we evaluated p-S65-Ub in human post-mortem brain tissue to better understand 
the association between alterations in mitoQC, age and PD neuropathology. Using novel 
antibodies [25, 26] we characterized the morphology and subcellular localization of p-S65-Ub 
along with organelle and disease markers. In addition, we quantified p-S65-Ub levels across 5 
regions from large cohorts of neurologically normal controls and cases with clinically diagnosed 
parkinsonian syndrome and pathologically confirmed LBD. Correlations of findings with 
clinicopathological data, revealed an age- and a disease-dependent increase of the mitophagy 
label in human brain. Moreover, p-S65-Ub not only co-existed but also correlated with SNCA 
and MAPT pathology in distinct areas of LBD brains. Our data emphasizes the relevance of 
PINK1-PRKN-directed mitoQC and suggest that p-S65-Ub may serve as a novel biomarker for 
mitochondrial damage in aging and disease.  
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Results 
Morphology and distribution of p-S65-Ub immunopositive structures in human brains. 
To analyze mitoQC in human post-mortem brain, PD vulnerable regions including the SN, 
hippocampus, amygdala, putamen and nbM were stained with the anti-p-S65-Ub mitophagy 
marker. We had previously developed and extensively characterized these antibody tools [25, 
26]. Twenty-eight cases from a neurologically normal cohort (hereafter referred to as controls) 
and 28 cases with pathologically-confirmed LBD from a spectrum of clinically diagnosed PD, 
PDD, and DLB patients were included in the study (see Table 1 for an overview of the cohorts as 
well as Tables S1 and S2 for details of controls and LBD cases, respectively).  
 Close inspection of brain sections revealed 3 major types of p-S65-Ub immunopositive 
structures in both controls and LBD cases: granules, granulovacuolar degeneration bodies 
(GVBs) and beaded neurites (Fig. 1A). The specificity of the staining was corroborated on 
adjacent brain sections with another commercially available antibody against p-S65-Ub that 
revealed exactly the same pattern, though was overall less sensitive in multiple applications (Fig. 
S1). All 3 p-S65-Ub-positive structures had distinct distributions across different brain regions 
(Fig. 1B). Punctate p-S65-Ub granules were frequently found in the cytoplasm of neuromelanin-
containing cells in the SN and occasionally in neurons in the amygdala and nbM. Meanwhile, 
strong immunoreactivity for p-S65-Ub was observed in small spherical structures within 
pyramidal neurons in the hippocampus and amygdala that were morphologically consistent with 
GVBs seen in aging and Alzheimer disease. Whereas these structures have been reported to stain 
positive with various phospho-specific antibodies [27], GVBs also contain ubiquitinated proteins 
and have been described as specific forms of residual autophagic bodies with incomplete 
degradation [28, 29]. p-S65-Ub labeled GVBs were found in the nbM as well, but to a much 
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lesser extent. In general, somatic p-S65-Ub staining, including granules and GVBs, were most 
abundant in the SN and hippocampus, followed by amygdala and then nbM. In contrast, p-S65-
Ub-positive beaded neurites were frequent in the nbM, less in the SN, and even less common in 
the hippocampus and amygdala. Putamen was almost devoid of any p-S65-Ub-immunopositive 
structures.  
In order to further validate the specificity of the p-S65-Ub antibodies in human post-
mortem brain tissue, we included available samples from PINK1 or PRKN mutation carriers 
(Table 1 and Table S3). Compared to age-matched sporadic LBD, PINK1 or PRKN mutant cases 
showed a dramatic reduction of somatic p-S65-Ub levels in the SN (Fig. 2; p=0.0006 and 
p=0.006, respectively). This is consistent with roles of both enzymes in joint catalysis and 
amplification of p-S65-Ub chains and impairments in labeling damaged mitochondria due to loss 
of either function. Among 2 algorithms we developed for unbiased p-S65-Ub quantification, the 
positive pixel count algorithm allowed capture of all p-S65-Ub structures, but was very sensitive 
to nonspecific signals from lipofuscin and other non-cellular structures; the positive cell count 
algorithm had superior specificity and was equally sensitive for granular and vacuolar somatic p-
S65-Ub (Fig. S2). Though beaded neurites were undetectable with the latter algorithm, we here 
chose this more stringent approach and focused on the cell soma where most mitochondria, 
autophagosomes and lysosomes are located. 
 
High resolution imaging analyses of p-S65-Ub-positive structures. 
To better characterize the p-S65-Ub-positive structures on a subcellular level, we used super-
resolution microscopy of LBD sections double labeled with other cellular markers. In the SN, 
small somatic p-S65-Ub granules showed partial colocalization with the mitochondrial marker 
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PPIF/cyclophilin F (peptidylprolyl isomerase F), and greater colocalization with the lysosomal 
marker CTSD (cathepsin D) (Fig. 3A, B). Interestingly, beaded neurites also colocalized with 
mitochondrial, but not lysosomal markers. In line with the idea that the autophagic degradation 
of mitochondria may occur predominantly in the cell body, co-labeling allowed the identification 
of distinct p-S65-Ub structures during mitoQC that potentially represented the mitochondrial 
pools in cell processes and lysosomal pools in the soma, respectively. In addition, as remnants of 
autophagic organelles [30], CSNK1D (casein kinase 1 delta)-positive GVBs in the hippocampus 
strongly colocalized with both p-S65-Ub and SSBP1 (single stranded DNA binding protein 1), 
another mitochondrial marker (Fig. 3C), suggesting an accumulation of p-S65-Ub-labeled 
mitochondrial components in autophagic bodies.  
To further examine the ultrastructure of p-S65-Ub-positive labels, we developed pre-
embedding techniques for immuno-electron microscopy. As a control, we first performed p-S65-
Ub immunostainings in HeLa cells stably expressing PRKN. Increased p-S65-Ub levels in the 
cytoplasm were observed specifically upon treatment with the depolarizer carbonyl cyanide m-
chlorophenyl hydrazone (CCCP) with both immunofluorescent and immunocytochemical 
staining methods (Fig. S3A, B). Consistent with the colocalization of p-S65-Ub and TOMM20 
(translocase of outer mitochondrial membrane 20), examination of cells with immunoelectron 
microscopy confirmed p-S65-Ub signals at the mitochondrial outer membrane (Fig. S3C). 
Similarly, analyses of human post-mortem tissue stained with p-S65-Ub antibodies showed 
intense signals on mitochondrial outer membranes. This was seen in both cytoplasm (Fig. 3D, 
top) and processes of cells (Fig. 3D, bottom) indicated by the nearby neurofilament-like 
structure. Vacuolar-shaped GVBs were also labeled with p-S65-Ub, some of which contained 
spherical structures with double membranes that could represent mitochondria undergoing 
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degradation (Fig. 3E). In some neurons, distinctly labeled GVB structures were adjacent to 
paired helical filaments (Fig. 3F). No immunolabeling was found in sections where the primary 
or secondary antibodies were omitted (data not shown). Taken together, the patterns seen for p-
S65-Ub in light microscopy were confirmed by electron microscopy. 
 
p-S65-Ub increases with age and disease, and enhanced levels in LBD brain are age- and 
Braak tangle stage-dependent.  
To assess mitoQC during aging, intracellular p-S65-Ub inclusions in the above 5 brain regions 
vulnerable to Lewy-related pathology were quantified in controls and analyzed based on age at 
death, concurrent neurofibrillary (Braak tangle stage) and amyloid (Thal amyloid phase) 
pathology (Fig. 4A-C and Fig. S4A-C). Of note, Braak tangle stages I-III are seen with normal 
aging and do not necessarily imply dementia [31]. Significant correlations of p-S65-Ub levels 
with age were observed in the hippocampus, amygdala, and nbM. In the same brain regions, p-
S65-Ub levels were also significantly correlated with Braak tangle stage. No age or Braak tangle 
stage effect was found in the SN or putamen within the control cohort and no effect of Thal 
amyloid phase was detected in any of the 5 brain regions studied  
 Next, we quantified p-S65-Ub in LBD cases (Fig. 4D-F and Fig. S4D-F) with a 
significant loss of neuromelanin-containing cells in the SN (p<0.0001) (Fig. S5). Significant 
correlations of p-S65-Ub levels with Braak tangle stage were observed in the hippocampus and 
amygdala, but not with age at death or Thal amyloid phase in any of the 5 brain regions. We then 
examined correlation of p-S65-Ub with 2 scoring systems for SNCA pathology [7, 32, 33]. 
While no difference was observed among LBD subtypes (brainstem predominant [BLBD], 
transitional [TLBD], and diffuse neocortical [DLBD]), a trend of correlation with Braak PD 
stage was detected in the amygdala (p=0.01) (Fig. S6). No correlations were found with any of 
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the other demographic characteristics including primary presenting clinical feature 
(parkinsonism versus cognitive decline), disease duration or age at onset (Fig. S7).  
 Due to the significant effects of age and Braak tangle stage on p-S65-Ub signal, controls 
and LBD brains were compared to determine the disease-specific effect (Table 1 and Fig. 5A). 
Younger controls were excluded to obtain age-matched cohorts (see Table S1 for details). 
Overall, LBD brains had significantly higher p-S65-Ub levels in the SN and hippocampus 
(p<0.0001 and p=0.001, respectively), which remained significant (p≤0.001) after adjusting 
individually for age, sex and Braak tangle stage. Of note, adjustment for amyloid-β plaques was 
not possible due to lack of higher Thal amyloid phase in controls. While, increased p-S65-Ub 
levels in the amygdala and nbM were age driven, the effects in the SN were disease driven. 
Hippocampal p-S65-Ub levels were associated with both, but showed a stronger association with 
disease status (control vs. LBD) than age as examined by multivariable linear regression models 
(Age: p=0.016, β: 0.012; Disease status: p=0.0001, β: 0.62).  
In the SN, LBD cases had significantly increased p-S65-Ub levels compared to controls 
in both younger (56-75 years old, p=0.004) and older (76-94 years old, p=0.0002) age groups 
(Fig. 5B). Such an increase was also observed in the hippocampus in the younger group 
(p=0.004). At more advanced Braak tangle stage (Fig. 5C) LBD cases also showed significantly 
elevated p-S65-Ub levels in the SN and hippocampus (p=0.0002 and p=0.0004, respectively). 
Regardless of age or Braak tangle stage, no significant differences in p-S65-Ub levels were 
found between controls and LBD cases in the amygdala, putamen or nbM. 
 
 
Interactions between p-S65-Ub, SNCA and MAPT in the LBD cohort 
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To investigate the interaction of p-S65-Ub with other PD pathological markers, we quantified LB 
and tangle density by immunostaining for correlations and used super-resolution microscopy for 
colocalization studies. As expected, LBD cases had significantly more LBs than age-matched 
controls in all 5 brain regions (p<0.0001) (Fig. 6A and Fig. S8A). A significant correlation of p-
S65-Ub and LB density was identified in the amygdala (Fig. 6B). Interestingly, in the SN from 
LBD cases, super-resolution microscopy revealed clear colocalization of SNCA 
immunoreactivity (LB509) with p-S65-Ub-positive beaded neurites, but only partial 
colocalization with somatic p-S65-Ub granules (Fig. 6C). Neither of the p-S65-Ub positive 
structures colocalized with phosphorylated SNCA (p-S129-SNCA), the pathological form of 
SNCA (Fig. S8C). Moreover, we observed a negative association of p-S65-Ub levels and LB 
pathology progression. Cells with small SNCA aggregates (pre-LBs) had abundant p-S65-Ub 
granules, whereas cells with dense-core (more mature) LBs only occasionally had surrounding p-
S65-Ub granules that closely decorated the surface of the LB (Fig. 6D). Strikingly, no p-S65-Ub 
signals were found in cells with typical brainstem type mature LBs.  
 In addition to SNCA pathology, LBD cases also had more neurofibrillary tangles in the 
nbM and a trend in the hippocampus (p=0.0006 and p=0.01, respectively) compared to controls 
(Fig. 7A and Fig. S9A). Significant correlations of p-S65-Ub and tangle levels were found in 
both hippocampus and amygdala of LBD cases (Fig. 7B). Super-resolution microscopy on 
hippocampal sections from LBD cases showed that p-S65-Ub-positive GVBs partially 
overlapped with phosphorylated MAPT staining for both MAPT antibodies marking early 
(CP13; p-S202-MAPT) and late (PHF-1; p-S396- and p-S404-MAPT) MAPT pathology (Fig. 7C 
and Fig. S9C) [29]. Of note, some p-S65-Ub-positive granules appeared trapped in large 
pretangle filamentous networks (Fig. 7D and Fig, S9D). In general, p-S65-Ub-positive GVBs 
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were abundant in cells with pre-tangles, but were less frequent in neurons with mature tangles. In 
summary, the degree of colocalization of p-S65-Ub, a marker of mitoQC, with SNCA and 
MAPT varied depending on progression of LB and tangle formation. 
  
Ac
ce
pte
d M
an
us
cri
pt
15 
 
Discussion 
Despite enormous insights gained into the molecular mechanisms of PINK1-PRKN-directed 
mitoQC over the past few years [17], truly disease-relevant data remain scarce. Studies in 
primary neurons or in model organisms have been hampered by the lack of sensitive tools and 
the dynamics of mitophagy, where flux through the degradation arm and counterbalancing 
mitochondrial biogenesis challenge unambiguous interpretation. Of note, an earlier study had 
already described altered mitophagy in post-mortem LBD brains [34], long before the discovery 
of the PINK1-PRKN pathway [35-38]. Here, we confirm the disease relevance and fill an 
important gap between the initial pathological observation and an extensive body of 
predominantly cellular/biochemical studies. We characterized p-S65-Ub morphology by high-
resolution microscopy, and objectively quantified levels of this novel mitophagy tag in 
neurologically normal controls and LBD cases across 5 different brain regions. Our findings 
indicate that alterations of mitoQC occur during normal aging and with progression of PD. 
Moreover, LBD brains accumulate p-S65-Ub already at a relatively early age in both the SN and 
hippocampus. Significant correlations of p-S65-Ub with SNCA and MAPT pathology and their 
co-existence at pre-mature stages were discovered, suggesting a potential early interaction. The 
disease-dependent increase of p-S65-Ub in the SN and its distinct staining pattern with SNCA 
provide further evidence linking mitoQC dysfunction with PD pathology. Interestingly, we found 
close interaction between p-S65-Ub, GVBs and p-MAPT in the hippocampus, revealing a 
region-specific crosstalk between mitochondrial damage/mitophagy and tauopathy in PD and 
possibly also other neurodegenerative disorders [39].  
 While it remains uncertain what exactly triggers activation of PINK1-PRKN-dependent 
mitoQC in vivo, organelle damage caused by mitochondrial DNA mutations, misfolded 
Ac
ce
pte
d M
an
us
cri
pt
16 
 
mitochondrial proteins and proteotoxic stress may be highly relevant factors [40-42]. In addition, 
it has become clear that the process is likely very localized and restricted to a few mitochondria 
or even submitochondrial regions at a time, as opposed to wholesale mitophagy observed in cell 
lines upon mitochondrial depolarization. p-S65-Ub is a dynamic degradation signal that is 
rapidly turned over under physiological conditions and therefore detectable only at low levels. 
Here we identified distinct p-S65-Ub-immunopositive structures that differed in terms of their 
distributions across brain regions and their colocalization with mitochondrial, autophagic, and/or 
lysosomal markers. PINK1-PRKN-dependent mitoQC was reported to occur locally in distal 
axons as well as in the neuronal cell bodies upon retrograde transport in different neuronal 
cultures [43, 44]. However, studies with recently developed fluorescent mitophagy reporter mice 
indicate that general turnover occurs mostly in neuronal somata in vivo [45]. Observed co-
labeling of p-S65-Ub-positive beaded structures with mitochondrial, but not lysosomal markers, 
may indicate labeled mitochondria en route to lysosomal degradation in the soma. In this context 
it is important to point out that several other mitophagy pathways have been identified that may 
operate in parallel to or may cross-talk with PINK1-PRKN-p-S65-Ub signaling. These include 
different receptor- [46] and lipid-mediated [47, 48] pathways that recruit phagophores 
independent of ubiquitin via direct binding to MAP1LC3A family members.  
Unbiased quantification in neurologically normal brains revealed significantly increased 
p-S65-Ub-positive cells in aged individuals compared to young controls. This is likely indicative 
of a pathological situation, possibly resulting from greater mitochondrial damage, a general 
decrease of autophagic/lysosomal clearance, or a combination of both. This is further consistent 
with a progressive decline in mitochondrial quality and function seen in aging and age-related 
diseases [49] and a reduced flux of general mitophagy in reporter mice with increased age [50]. 
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The PINK1-PRKN pathway appears to protect organisms from aging-induced mitochondrial 
dysfunction, mitigate mitochondria DNA mutation accumulation, and foster longevity in animal 
models [51, 52]. Our data provides additional evidence for mitoQC dysfunction in aging human 
brain, and suggest the hippocampus, amygdala and nbM as particularly vulnerable regions. 
When comparing age-matched controls and LBD cases, p-S65-Ub granules were prominently 
increased in the SN across all age groups. During the preparation of this manuscript, a similar 
punctate p-S65-Ub signal was reported in 1 PD case using the commercial p-S65-Ub antibody 
though with less resolution of specific colocalization [53]. While PINK1 and PRKN are broadly 
neuroprotective [54], dopamine neurons appear particularly vulnerable to their dysfunction, 
possibly due to their high firing rate, Ca2+ load, extreme arborization, and the chemical 
properties of dopamine itself [14, 55]. Our data provide further evidence for considerable 
mitoQC alterations in dopamine neurons, which could contribute to their susceptibility towards 
neuronal death in PD. The increased p-S65-Ub level in the hippocampus of LBD cases may 
contribute to non-motor symptoms, such as cognitive impairment, in LBD.  
Both SNCA and MAPT cause impairments of several steps of the mitoQC pathway, from 
induction of mitochondrial dysfunction to inhibition of autophagy/lysosomal clearance [24, 39, 
56-58], thus possibly resulting in enhanced p-S65-Ub levels as shown in the current study. 
Impaired mitoQC also has reciprocal effects on SNCA aggregation and MAPT phosphorylation 
[57, 58]. Several of the above mechanisms could work simultaneously to reduce overall 
neuroprotection of PINK1-PRKN-directed mitoQC, which might be overcome by PINK1 or 
PRKN overexpression [59, 60]. In addition, the observation of more p-S65-Ub in cells with pre-
mature SNCA or MAPT pathology in the SN or hippocampus, respectively, suggests that the 
brain region-specific crosstalk between synucleinopathy or tauopathy and mitoQC might happen 
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early on. The exact mechanisms, distinct SNCA and p-MAPT species and their particular 
functions or dysfunctions that could have an impact upon mitoQC at different steps need to be 
studied in the future.  
 Taken together, increased p-S65-Ub levels demonstrate age- and disease-specific 
alterations of mitoQC and point to the potential convergence of multiple pathways. Going 
forward p-S65-Ub may be used as a biomarker and quantitative trait to identify modifiers and 
determine the relative contributions of mitochondrial dysfunctions, impaired neuronal transport 
and/or defective proteostasis to the pathogenesis of disease. 
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Material and Methods 
Study subjects 
A total of 28 neurologically normal controls, 28 sporadic LBD and 9 PINK1 and PRKN mutation 
carriers were obtained from the Mayo Clinic Florida Brain Bank. All brains were examined in a 
systematic and standardized manner and obtained between 1998 and 2015. Detailed 
characteristics of these 3 cohorts are summarized in Tables S1-S3, respectively. All subjects are 
non-Hispanic Caucasians of European descent. Available clinical information included besides 
basic demographics, age at onset, disease duration and initial symptoms. The clinical diagnosis 
of the majority of the LBD cases was PD and PDD, with one case of DLB. The LBD cohort was 
systematically screened with no mutations in known familial PD genes identified and was further 
subtyped with SNCA staining into BLBD (n=7), TLBD (n=17) and DLBD (n=4) [7, 32, 61]. 
Additional neuropathological information was collected, including age at death, Braak PD stage 
for SNCA (0-6) and Braak tangle stage for MAPT (0-VI) as well as Thal amyloid phase for 
amyloid-β plaques (0-5) [33, 62]. Cases with higher Braak tangle stages (>III) had been excluded 
to focus on PD- and not Alzheimer disease-related pathology, and intermediate categories were 
created for borderline cases. For analysis of low and medium Braak tangle stage groups, we 
collapsed cases with Braak tangle stage 0, 0-I, I and I-II as ‘<II’ group and cases with Braak 
tangle stage II, II-III and III as ‘≥II’ group. For comparisons between controls and LBD cases 
and between controls, LBD and mutation carriers, we utilized different subgroups of controls and 
LBD cases that were similar with regard to age at death and Braak tangle stage (compare Tables 
S1 and S2). The Mayo Clinic brain bank for neurodegenerative disorders operates with approval 
of the Mayo Clinic Institutional Review Board. All brain samples are from autopsies performed 
after approval by the legal next-of-kin. Research on de-identified postmortem brain tissue is 
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considered exempt from human subjects regulations by the Mayo Clinic Institutional Review 
Board. 
 
Immunohistochemistry and image analysis  
Sections from paraffin embedded post-mortem brain tissue were cut at a thickness of 5 microns 
and allowed to dry overnight in a 60°C oven. Following deparaffinization and rehydration, target 
retrieval was performed by steaming the sections for 30 min in deionized water. Immunostaining 
was performed with a Dako Autostainer using Envision Plus kit (Agilent, K4011 and K4007). 
Endogenous peroxidase was blocked for 5 min with 0.03% hydrogen peroxide (Agilent, K4011 
and K4007). Sections were then treated with 5% normal goat serum (Invitrogen, 16210072) for 
20 min. Subsequently, sections were incubated for 45 min at room temperature using primary 
antibodies against p-S65-Ub (in-house [25]; 1:1000; Millipore Sigma, ABS1513; 1:50), SNCA 
(Invitrogen, 180215; 1:3000), or p-S202-MAPT (monoclonal antibody from Peter Davies, 
Feinstein Institute, CP13; 1:1000). After incubation with primary antibody, sections were 
incubated in Envision-Plus rabbit- or mouse-labeled polymer HRP (Agilent, K4011 and K4007) 
for 30 min at room temperature. Peroxidase labeling was visualized with the chromogen solution 
3,3'-diaminobenzidine (Agilent, K4011 and K4007). The sections were then counterstained with 
Lerner 1 hematoxylin (Fisher Scientific, CS400-1D) and coverslipped with Cytoseal mounting 
medium (Thermo Scientific, 8310). For midbrain sections that contain neuromelanin-positive 
cells in the SN, peroxidase labeling was visualized with HighDef Blue (Enzo Life Sciences, 
ADI-950-151). Sections were coverslipped without counterstain using aqueous mounting 
medium (Thermo Scientific, TA-030-FM). After drying, all sections were scanned with an 
Aperio AT2 digital pathology scanner (Leica Biosystems, Wetzlar, Germany). Sections stained 
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with p-S65-Ub, SNCA and p-S202-MAPT were traced and quantified using optimized Aperio 
Immunohistochemistry Image Analysis algorithms to deteermine the p-S65-Ub-positive cell 
count, LB count and tangle count. p-S65-Ub cell, LB and tangle density was calculated by 
dividing the positive cell count by the traced area. 
 
Meso Scale Discovery electrochemiluminescence assays 
 
To detect synthetic p-S65-Ub (custom-made at Thinkpeptides) [25] via Meso Scale Discovery 
assay, 96-well plates were coated with in-house or commercial (Millipore Sigma, ABS1513) p-
S65-Ub antibodies at a final concentration of 3.08 µg/ml in carbonate-bicarbonate coating buffer 
(15 mM Na2CO3, 35 mM NaHCO3,  pH 9.4) and incubated overnight at 4°C. Plates were washed 
3 times with TBST (50 mM tris base, pH 7.4, 150 mM NaCl, 0.05%  Tween-20 [Sigma-Aldrich, 
P1379]) blocked with 5% BSA (Boston BioProducts, P-753) in TBST for 2 h, shaking (350 rpm) 
at room temperature, and then washed again. To compare sensitivity of different p-S65-Ub 
antibodies, synthetic p-S65-Ub was serially diluted in 1% BSA in TBST to a final concentration 
of 0.78 ng to 50 ng. Unmodified recombinant Ub (Boston Biochem, U-100H) served as a 
negative control. Samples were added to the plate and incubated for 1 h at room temperature, 
shaking at 350 rpm. Plates were washed and detection antibody (Millipore Sigma, MAB1510) 
diluted 1:500 in 1% BSA TBST was added for 1 h. After 3 washes with TBST goat anti-mouse 
SULFO TAG detection antibody (Meso Scale Discovery, R32AC; 1: 500 in 1% BSA TBST) was 
added to each well and incubated with shaking for 1 h at room temperature. Plates were washed 
and 1x read buffer T with surfactant (Meso Scale Discovery, R92TC) was added to each well, 
followed by plate reading on the SECTOR Imager 2400A (Meso Scale Discovery, Rockville, 
MD, USA). 
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Cell culture, treatment and western blot 
 HeLa cells stably expressing PRKN [63] were grown in Dulbecco’s modified Eagle medium 
(Invitrogen, 11965118) supplemented with 10% fetal bovine serum (Biowest, S1620) at 37°C 
under humidified conditions in 5% CO2:air. Cells were seeded on 6-well plates and incubated 
with or without 10 µM CCCP (Sigma-Aldrich, C2759) in medium for 4 h. 
After the treatment, cells were lysed in RIPA lysis buffer (50 mM Tris, pH 8.0, 150 mM 
NaCl, 0.1% SDS, 0.5% deoxycholate [Sigma-Aldrich, D6750], 1% NP-40/Igepal [Sigma-
Aldrich, I3021] containing protease inhibitor cocktail and phosphatase inhibitors [Sigma-
Aldrich, 11697498001 and 04906837001]). Cell lysates were cleared for 15 min at 20817 rcf. 
Protein content was determined by BCA assay (Thermo Fisher, 23225). Cell lysates were diluted 
in Laemmli buffer (62.5 mM Tris, pH 6.8, 1.5% SDS, 8.33% glycerol, 1.5% β-Mercaptoethanol, 
0.005% bromophenol blue) and boiled at 95°C for 5 min. Protein was subjected to SDS-PAGE 
using 8-16% Tris-Glycine gels (Invitrogen, EC60485BOX). Proteins were transferred onto 
polyvinylidene fluoride membranes (Millipore Sigma, IPVH00010). Post transfer, membranes 
were washed in TBST, blocked in 5% skim milk (Thermo Scientific, OXLP0031B) and 
incubated with primary antibodies against p-S65-Ub (in-house or Millipore Sigma, ABS1513) at 
0.05, 0.25, 0.5 or 1 µg/ml using a multiscreen apparatus overnight at 4°C, followed by washing 
in TBST. Secondary HRP-conjugated antibodies diluted in 5% milk in TBST (Jackson 
ImmunoResearch, 111-035-003; 1:10,000) were added for 1 h at room temperature. Bands were 
visualized after washing in TBST using Immobilon Western Chemiluminescent HRP Substrate 
(Millipore Sigma, WBKLS0500) on a Fuji LAS-3000 (Fujifilm Life Science USA, Stamford, 
CT, USA) system using a program with pre-set exposure times. For comparing different 
antibodies in the detection of peptide, N-terminal biotinylated p-S65-Ub (custom-made at 
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Thinkpeptides) [25] was run on the gel at serial dilution from 10-500 ng and detected with 0.75 
µg/ml p-S65-Ub antibodies (in-house [25] or Millipore Sigma, ABS1513). The N-terminal 
biotinylated non-modified ubiquitin (Boston Biochem, UB-560) was run on the same gel as 
negative control and HRP-coupled streptavidin (Pierce, 21130) was used as a loading control. 
 
High-content imaging 
To quantify the p-S65-Ub, automated high-content imaging was employed as recently described 
[25]. In brief, cells were seeded in 96-well imaging plates (Fisher Scientific, 08772225) and 
allowed to attach overnight. Cells were then treated for 0, 2, 4, or 8 h with 10 µM CCCP. Cells 
were washed once in PBS (Boston BioProducts, BM-220), fixed for 10 min in 4% 
paraformaldehyde (Sigma-Aldrich, 441244) and permeabilized with 1% Triton X-100 (Fisher 
Scientific, BP151) in PBS. Cells were stained using different concentrations of p-S65-Ub 
antibodies (0.1 and 0.5 µg/ml) (in-house [25] or Millipore Sigma, ABS1513) and with Hoechst 
33342 (Invitrogen, H21492l; 1:5000). Plates were imaged on a BD Pathway 855 (BD 
Biosciences, San Jose, CA, USA) with a 20x objective using a 2x2 montage (no gaps) with laser 
autofocus every second frame. Raw images were processed using the built-in AttoVision V1.6 
software. Regions of interest were defined as nucleus and cytoplasm using the built-in ‘RING-2 
outputs’ segmentation for the Hoechst channel after applying a shading algorithm. Background 
signal at 0 h was subtracted for each antibody and values were normalized to the highest value (8 
h CCCP in-house antibody). 
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Immunostaining of cells 
Cells were seeded on glass coverslips coated with poly-D-lysine hydrobromide (Sigma-Aldrich, 
P6407) and incubated with or without 10 µM CCCP in medium for 4 h. After fixation with 4% 
paraformaldehyde, cells were permeabilized with 0.05% Triton X-100 in PBS and blocked with 
10% normal goat serum. For immunofluorescence, cells were incubated with primary antibodies 
against p-S65-Ub (in-house; 1:260) [25] and TOMM20 (Santa Cruz Biotechnology, sc-17764; 
1:50), followed by incubation with secondary antibodies (Invitrogen, A-11034 and A-11004; 
1:1000). Nuclei were stained with Hoechst 33342 diluted 1:5,000. Coverslips were mounted onto 
microscope slides using fluorescence mounting medium (Agilent, S302380). For 
immunocytochemistry, cells were incubated with primary antibody against p-S65-Ub (in-house; 
1:500) [25] and then in Envision-Plus rabbit-labeled polymer HRP (Agilent, K4011). Peroxidase 
labeling was visualized with 3,3'-diaminobenzidine (Agilent, K4011). Cells on coverslips were 
then counterstained with Lerner 1 hematoxylin mounted with Cytoseal mounting medium after 
dehydration and clearing. 
 
Immunofluorescence and imaging of human brain tissue 
Following target retrieval, human brain sections were blocked with serum-free protein block 
(Agilent, X0909) for 1 h at room temperature and incubated in primary antibodies against p-S65-
Ub (in-house; 1:500) [25], PPIF (Abcam, ab110324; 1:500), CTSD (Millipore Sigma, IM03; 
1:1000), CSNK1D (Santa Cruz Biotechnology, sc-55553; 1:50), SNCA (Invitrogen, 180215; 
1:100), p-S129-SNCA (Wako Chemicals USA, 015-25191; 1:3000), p-S202-MAPT (monoclonal 
antibody from Peter Davies, Feinstein Institute, CP13; 1:250) or p-S396- and p-S404-MAPT 
(monoclonal antibody from Peter Davies, PHF-1; 1:500) diluted with antibody diluent with 
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background reducing components (Agilent, S302283) at 4°C overnight in a humidity chamber. 
The next day sections were incubated with secondary antibodies (Invitrogen, A-11034 and A-
11004; 1:1000) and DAPI (Sigma-Aldrich, D9542; 1:1000) at room temperature for 1.5 h. 
Autofluorescence signal was quenched using 3% Sudan black (SPI Supplies, 02560-AB) in 70% 
MeOH (Pharmco-Aaper, AAP-1031) for 2 min before coverslipping slides using fluorescence 
mounting medium. Super-resolution confocal (Airyscan) fluorescence images were taken with a 
Zeiss observer LSM 880 microscope equipped with 405-, 488-, 543-, and 633-nm lasers (Zeiss, 
Oberkochen, Germany).  
 
Pre-embedding immunoelectron microscopy 
Vibratome sections (40 μm) of formalin-fixed human brains were processed for 
immunohistochemistry using 3,3'-diaminobenzidine as chromogen. The areas with 
immunolabeled structures were dissected, fixed in 2.5% glutaraldehyde (Electron Microscopy 
Science, 16020)-0.1 M cacodylate buffer (Electron Microscopy Science, 11652), post-fixed in 
2% aqueous osmium tetroxide (Electron Microscopy Science, 19150), en block stained in 2% 
uranyl acetate (Electron Microscopy Science, 22400) in 50% EtOH (Pharmco-Aaper, 
241ACS200CSGL), dehydrated in EtOH and propylene oxide (Electron Microscopy Science, 
20401), then infiltrated and embedded in Epon 812 (Polysciences, Inc., 08791). Thin sections 
were collected on formvar-coated grids (Electron Microscopy Science, FF100-Cu) and examined 
without counter staining in a Philips 208S electron microscope, fitted with a Gatan 831 Orius 
CCD digital camera (Gatan, Pleasanton, CA, USA). Digital micrographs were processed with 
Adobe Photoshop CS5 software.  
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Statistical analysis 
Given that most p-S65-Ub measures were not normally distributed, we used non-parametric tests 
for all analyses. Specifically, a Wilcoxon rank sum test was used for comparisons of p-S65-Ub 
measures between 2 groups, whereas a Kruskal-Wallis test was used for comparisons involving 
more than 2 groups. Additionally, for comparisons of p-S65-Ub measures between normal and 
LBD groups, in order to adjust for any potential confounding influences of age at death, sex, and 
Braak tangle stage, we used a van Elteren stratified Wilcoxon rank sum test adjusting 
individually for these variables [64]. Spearman’s test of correlation was used to assess the 
association between p-S65-Ub and demographic information or other biomarkers in each brain 
region. In order to account for the fact that all statistical tests involving p-S65-Ub were 
performed using measures in 5 different brain regions, we considered p-values of 0.01 or lower 
as statistically significant after applying a Bonferroni correction for multiple testing. Statistical 
analyses were performed using SAS (SAS Institute, Inc; version 9.2) and GraphPad Prism 
(GraphPad Software; version 7). 
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Abbreviations 
BLBD  brainstem predominant Lewy body disease 
CCCP  carbonyl cyanide m-chlorophenyl hydrazone 
DLB   dementia with Lewy bodies  
DLBD  diffuse neocortical Lewy body disease 
EOPD   early-onset Parkinson disease 
GVB   granulovacuolar degeneration body 
LB   Lewy body 
LBD   Lewy body disease 
mitoQC  mitochondrial quality control 
nbM   nucleus basalis of Meynert 
PD   Parkinson disease 
PDD   Parkinson disease with dementia 
p-S65-Ub PINK1-phosphorylated serine 65 ubiquitin 
SN   substantia nigra 
TLBD   transitional Lewy body disease 
Ub  ubiquitin 
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Figure legends 
Figure 1. Morphology and distribution of p-S65-Ub-immunopositive structures. (A) Adjacent 
sections from LBD brains were stained with different p-S65-Ub antibodies at the indicated 
concentrations. Representative images of p-S65-Ub-immunopositive structures from various 
brain regions show the same 3 major patterns: granules (left panels), GVBs (middle panels) and 
beaded neurites (right panels). (B) Representative images of human brain sections from normal 
(left) and LBD cases (right) stained with p-S65-Ub antibody are shown. Chromogen used for the 
SN was HighDef Blue (blue) to distinguish the positive signal from dark brown neuromelanin in 
DA neurons. Conventional brown 3,3'-diaminobenzidine was used as a chromogen for all other 
brain regions (hippocampus, amygdala, putamen, and nbM). A magnified image of the boxed 
area is shown to the right. Scale bars: 20 µm. 
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Figure 2. Reduced or absent p-S65-Ub staining in brains from PRKN or PINK1 mutation 
carriers. (A) SN sections from controls, sporadic LBD and cases with PINK1 or PRKN mutations 
were stained with p-S65-Ub antibody. Representative images of stained sections show enhanced 
p-S65-Ub levels in sporadic PD, but reduced or absent signal in SN of PRKN or PINK1 mutant 
cases. A magnified image of the boxed area is shown to the right. (B) Quantification of p-S65-
Ub signal in age-matched controls, sporadic LBD cases and mutation carriers. Kruskal-Wallis 
test, *p<0.01) n=17 for normal, n=19 for sporadic PD, n=7 for PD with PRKN mutation, and n=2 
for PD with PINK1 mutation.  
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Figure 3. High-resolution imaging and ultrastructural examination of human brain tissue 
immunolabeled with p-S65-Ub. Human brain sections from LBD cases were multicolor labeled 
with antibodies against p-S65-Ub and (A) PPIF (mitochondrial marker), (B) CTSD (lysosomal 
marker) or (C) CSNK1D (GVB marker) and SSBP1 (mitochondrial marker). Representative 
Airyscan confocal images from SN and hippocampus are shown. p-S65-Ub-immunopositive 
granules partially colocalized with both mitochondrial and lysosomal markers; beaded neurites 
were co-labeled only with mitochondrial, but not lysosomal markers. GVBs were partially co-
labeled with CSNK1D and mitochondrial markers. The colocalization of p-S65-Ub with the 
respective organelle markers is also demonstrated in the orthogonal (Ortho) view presented to 
the right. Scale bars: 5 µm. (D) Top: Mitochondria (black asterisks) are intensely labeled with p-
S65-Ub on the outer membrane. Bottom: Some mitochondria (white asterisk) were found next to 
a neurofilament-like structure (solid arrow). (E, F) Top: At lower magnification, structures 
labeled (triangle) are consistent with GVBs seen at light microscopy. Bottom: At higher 
magnification, spherical double-membrane structures, possibly mitochondria, are found in the 
GVBs (white asterisk and circled by dashed line). Some labeled GVBs are adjacent to paired 
helical filaments (open arrow). Scale bars: 1 µm. 
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Figure 4. p-S65-Ub cell density increases with advanced aging and Braak tangle stage in select 
brain regions in neurologically normal controls or in LBD. SN, hippocampus and amygdala from 
neurologically normal controls and LBD cases were stained with p-S65-Ub antibody. 
Correlations of p-S65-Ub cell density with age at death, Braak tangle stage and Thal amyloid 
phase was examined within either normal aging (A-C) or LBD cohort (D-F) (Spearman’s test of 
correlation, significance level: p<0.01). In controls, n=28 for SN, n=28 for hippocampus, n=22 
for amygdala. Putamen and nbM are shown in Fig. S4A-C. In LBD, n=21 for SN, n=28 for 
hippocampus, n=24 for amygdala. Putamen and nbM are shown in Fig. S4D-F.  
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Figure 5. LBD brains have significantly higher p-S65-Ub levels compared to age-matched 
controls in SN and hippocampus. (A) p-S65-Ub-positive cell density from all 5 brain regions was 
compared between age-matched controls and LBD cases (Wilcoxon rank sum test, *p<0.01). p-
S65-Ub-positive cell density was also compared within (B) different age and (C) Braak tangle 
stage groups (Wilcoxon rank sum test followed by adjustment with Bonferroni correction, 
*p<0.005). In controls, n=20 for SN, n=20 for hippocampus, n=16 for amygdala, n=16 for 
putamen, and n=15 for nbM. In LBD, n=21 for SN, n=28 for hippocampus, n=24 for amygdala, 
putamen, and nbM. All data are presented in scatter-plots showing the median and interquartile 
range.  
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Figure 6. Correlation and interaction of p-S65-Ub and SNCA pathology in LBD brains. (A) 
Lewy body density in SN, hippocampus and amygdala was compared between age-matched 
normal controls and LBD cases (Wilcoxon rank sum test, *p<0.01). Data are presented in 
scatter-plots showing the median and interquartile range. (B) The correlation between p-S65-Ub 
and Lewy body density in LBD brains was examined, and significant correlations were observed 
in the amygdala (Spearman’s test of correlation, significance level: p<0.01). In controls, n=20 for 
SN, n=20 for hippocampus, n=16 for amygdala. In LBD, n=21 for SN, n=28 for hippocampus, 
n=24 for amygdala. Putamen and nbM are shown in Fig. S7A, B. (C) SN sections of LBD cases 
were double immunostained with p-S65-Ub and SNCA antibodies. Cells with different stages of 
SNCA-positive aggregations are shown. A magnified image of the boxed area is shown to the 
right. p-S65-Ub (green) colocalizes with SNCA (red) more in beaded neurites than in granules in 
soma. p-S65-Ub levels appear to decline with maturation of SNCA into LBs. For double labeling 
with p-S129-SNCA, see Fig. S7C. (D) The spatial relationship of p-S65-Ub- and p-S129-SNCA-
positive LB is shown in 3D surface rendering. Scale bars: 5 µm.  
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Figure 7. Correlation and interaction of p-S65-Ub and MAPT pathology in LBD brains. (A) 
tangle density in SN, hippocampus and amygdala is compared between age-matched normal 
controls and LBD cases (Wilcoxon rank sum test, *p<0.01). Data are presented in scatter-plots 
with the median and interquartile range. (B) The correlation of p-S65-Ub with tangle density was 
examined in LBD, and significant correlations were observed in the hippocampus and amygdala 
(Spearman’s test of correlation, significance level: p<0.01). In controls, n=20 for SN, n=20 for 
hippocampus, n=16 for amygdala. In LBD, n=21 for SN, n=28 for hippocampus, n=24 for 
amygdala. Putamen and nbM are shown in Fig. S8A, B. (C) Hippocampal sections of LBD cases 
were double stained with p-S65-Ub and p-MAPT antibodies. A magnified image of the boxed 
area is shown to the right. Intracellular p-S65-Ub GVBs (green) are embedded in the MAPT 
network (red) labeled by late stage MAPT marker (PHF-1). For early-stage MAPT marker CP13, 
see Fig. S8C, D. p-S65-Ub levels appear to increase with maturation of tangles, but disappear in 
late-stage tangles. (D) The spatial relationship of p-S65-Ub and PHF-1 is shown in 3D surface 
(left) and maximum (right) rendering. Scale bars: 5 µm. 
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Table 1. Subject characteristics.  
Cohort N Median age     (25%-75%) Male (%) 
Braak tangle stage   
(25%-75%) 
Thal amyloid phase  
(25%-75%) 
Braak PD sta
(25%-75%
Normal* 28     68 (54-82) 17 (61%)  I (0-II) 0 (0-1)       0 (0-0) 
Sporadic LBD* 28    78 (70-84) 21 (75%)   II-III (I-III)           1 (0-2)       4 (3-5) 
Mutation carriers 9    78 (72-94) 5 (56%)   IV-V (II-V)           5 (1-5)       4 (3-5) 
Note: Neuropathological scores are presented as median (25th, 75th percentile).  Individual information regardin
each individual is provided in Tables S1-S3.  
* Subgroups of the cohorts used in different studies are indicated in Tables S1 and S2. 
Abbreviations: PD, Parkinson disease; LBD, Lewy body disease. 
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SUPPLEMENTARY MATERIAL  
Supplementary Figure Legends 
Figure S1. Comparison of in-house and commercial p-S65-Ub antibodies. (A) Meso Scale 
Discovery assay detection of synthetic p-S65-Ub and recombinant Ub. Plates were coated with 
3.08 µg/ml in-house or commercial p-S65-Ub antibodies. Different concentrations of synthetic p-
S65-Ub or unmodified recombinant Ub were added. Binding was quantified by detection with 
mouse anti-Ub antibodies and sulfo-tagged anti-mouse secondary antibodies. (B) Western blots 
of serially diluted p-S65-Ub or non-modified Ub were probed with 0.75 µg/ml p-S65-Ub 
antibodies. HRP-coupled streptavidin was used as a loading control. (C) Western blots prepared 
with lysates from HeLa cells stably expressing PRKN and treated for 4 h with 10 µM CCCP. 
Membrane was probed with different p-S65-Ub antibodies serially diluted to the indicated final 
concentrations. Lane 1 and 2 are probed with in-house or commercial p-S65-Ub antibodies, 
respectively. (D) High-Content Imaging of HeLa cells with PRKN stained with p-S65-Ub 
antibodies. Cells were left untreated or treated for 2, 4, or 8 h with 10 µM CCCP and stained 
with the indicated amounts of p-S65-Ub antibodies. Mean fluorescence intensity in the 
cytoplasm of the cells was quantified. After background subtraction, values were normalized to 
the highest value (8 h, in-house antibody). Shown is the mean value of 5 wells per condition +/- 
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SEM. Ab, antibody. 
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Figure S2. Comparison of algorithms for unbiased quantification of p-S65-Ub signals. Brain 
sections were stained with p-S65-Ub antibody and visualized with HighDef blue for the midbrain 
section (upper panel) or 3,3'-diaminobenzidine for other brain areas (lower panel). Areas of 
interest were traced and analyzed with 2 algorithms. A cell count algorithm was used to 
determine somatic p-S65-Ub-positive cell density. A positive pixel algorithm was used to assess 
p-S65-Ub-stained pixel count independent of cellular location. p-S65-Ub-positive beaded 
neurites (arrow heads) are only recognized by the positive pixel algorithm, but not the cell count 
algorithm, while p-S65-Ub granules and GVBs are detected by both. Scale bars: 20 µm.  
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Figure S3. Immunostaining and ultrastructure examination of p-S65-Ub in HeLa cells 
overexpressing PRKN. Cells were treated with or without CCCP, fixed and immunostained or 
examined with immunoelectron microscopy. (A) Cells were labeled with p-S65-Ub (green) and 
TOMM20 (mitochondria, red) antibodies as well as Hoechst (nucleus, blue). Scale bars: 20 µm. 
(B) Cells were stained with p-S65-Ub and 3,3'-diaminobenzidine (brown) and nuclei were 
counterstained with hematoxylin (purple). Scale bars: 20 µm. (C) Outer-membrane of selected 
mitochondria (asterisk) were labeled with p-S65-Ub (solid arrow) and visualized through pre-
embedding immunoelectron microscopy. Scale bars: 1 µm.  
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Figure S4. p-S65-Ub cell density in select brain regions in controls or in LBD. Putamen and 
nbM from neurologically normal controls and LBD cases were stained with p-S65-Ub antibody. 
Correlations of p-S65-Ub cell density with age at death, Braak tangle stage and Thal amyloid 
phase was examined within either normal aging (A) or LBD cohort (B) (Spearman’s test of 
correlation, significance level: p<0.01). In controls, n=22 for putamen, n=21 for nbM. In LBD, 
n=24 for putamen and nbM.  
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Figure S5. The LBD cohort has significantly lower neuromelanin-containing cells in the SN 
compared to age-matched controls. Neuromelanin-containing cell density in the SN was 
compared between age-matched controls and LBD cases (Wilcoxon rank sum test, *p<0.01). 
n=20 for controls and n=21 for LBD cases. Data are presented in scatter-plots with the median 
and interquartile range. 
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Figure S6. Association of p-S65-Ub levels with LBD subtypes and Braak PD stage in LBD. (A) 
p-S65-Ub levels in the SN, hippocampus, amygdala, putamen and nbM were compared among 
LBD subtypes (Kruskal-Wallis test). (B) Correlations of p-S65-Ub with Braak PD stage were 
examined for LBD cases (Spearman’s test of correlation, significant level: p<0.01). PathDX, 
pathological diagnosis; n=21 for SN, n=28 for hippocampus, n=24 for amygdala, putamen, and 
nbM.  
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Figure S7. Association of p-S65-Ub levels with clinical and demographic characteristics in LBD. 
(A) p-S65-Ub levels in different brain regions were compared between LBD cases with or 
without cognitive decline (Wilcoxon rank sum test). Data are represented by scatter plots with 
the median and interquartile range. Correlations of p-S65-Ub with (B) disease duration and (C) 
age of onset were examined for LBD cases (Spearman’s test of correlation, significant level: 
p<0.01). n=21 for SN, n=28 for hippocampus, n=24 for amygdala, putamen, and nbM.  
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Figure S8. Correlation and interaction of p-S65-Ub with SNCA pathology in LBD. (A) Lewy 
body density in putamen and nbM was compared between age-matched controls and LBD cases 
(Wilcoxon rank sum test, *p<0.01, left). Data are presented in scatter-plots showing the median 
and interquartile range. (B) The correlation between p-S65-Ub and Lewy body density in LBD 
brains was examined (Spearman’s test of correlation, significance level: p<0.01). In controls, 
n=16 for putamen, n=15 for nbM. In LBD, n=24 for putamen and nbM. (C) SN sections of LBD 
cases were double immunostained with p-S65-Ub and p-S129-SNCA antibodies. Cells with 
different stages of p-S129-SNCA-positive aggregates are shown. A magnified image of the 
boxed area is shown to the right. p-S65-Ub-positive granules and beaded neurites (green) do not 
colocalize with p-S129-SNCA (red). Scale bars: 5 µm.  
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Figure S9. Correlation and interaction of p-S65-Ub with MAPT pathology in LBD. (A) NFT 
density in the putamen and nbM was compared between age-matched controls and LBD cases 
(Wilcoxon rank sum test, *p<0.01). Data are presented in scatter plots with the median and 
interquartile range. (B) The correlation of p-S65-Ub with NFT density was examined in LBD 
(Spearman’s test of correlation, significance level: p<0.01). In controls, n=16 for putamen, n=15 
for nbM. In LBD, n=24 for putamen and nbM. (C) Hippocampal sections of LBD cases were 
double immunostained with p-S65-Ub (green) and the early stage MAPT marker CP13 (red). 
Cells with different stages of MAPT-positive aggregates are shown. A magnified image of the 
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boxed area is shown to the right. (D) The spatial relationship of p-S65-Ub and CP13 is shown in 
3D surface (left) and maximum (right) rendering. Scale bars: 5 µm.  
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Table S1. Characteristics of the neurologically normal cohort. 
PathDx Age Sex 
Braak tangle 
stage 
Thal amyloid 
phase 
Braak PD 
stage 
PMI 
Comparison 
vs. mutation carriers aging vs. sporadic LBD 
Normal 23 F 0 0 0 14 - + - 
Normal 26 F 0 0 0 / - + - 
Normala,b 30 M 0 0 0 17 - + - 
Normal 37 M 0 0 0 / - + - 
Normal 50 M 0 0 0 / - + - 
Normala,b 53 F 0 0 1 / - + - 
Normal 54 F I 0 / / - + - 
Normal 56 F 0 0 0 / - + + 
Normal 60 M 0 1 0 10 - + + 
Normal 63 M 0-I 2 0 / - + + 
Normal 63 M III 0 0 3 + + + 
Normal 64 F I 1 0 / + + + 
Normal 65 M 0 0 0 / + + + 
Normala,b 65 F 0 0 0 10 + + + 
Normal 70 M I 0 0 51 + + + 
Normal 74 M II 0 1 12 + + + 
Normalb 76 M III 1 0 6 + + + 
Normal 78 M II 1 0 13 + + + 
Normal 79 M I-II 0 0 / + + + 
Normal 81 M II 0 0 21 + + + 
Normal 81 M II 0 0 29 + + + 
Normal 82 F III 1 0 19 + + + 
Normal 85 M I 0 0 3 + + + 
Normala,b 88 F III 1 0 20 + + + 
Normal 91 F III 0 0 14 + + + 
Normala,b 93 M I 1 0 6 + + + 
Normala,b 94 M I 0 0 / + + + 
Normal 99 F III 0 / 9 - + - 
All Normal controls were Caucasian. Abbreviations: PathDX, pathological diagnosis; M, male; F, female; PD, Parkinson disease; PMI, post-mortem interval;  /, 
information unavailable.   
a Tissue from the amygdala and putamen were unavailable.                                                                                                                                                                               
b Tissue from the nucleus basalis of Meynert was unavailable. 
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Table S2. Characteristics of the sporadic LBD cohort. 
PathDx Age Sex 
Braak 
tangle 
stage 
Thal 
amyloid 
phase 
Braak 
PD 
stage 
PMI 
Disease 
duration 
Age 
of 
onset 
Clinical Dx 
First symptom: parkinsonism (PD) or cognitive 
decline 
vs. 
mutation 
carriers 
BLBDa 58 F 0 1 3 / 17 41 PD PD (tremor, rigidity) - 
TLBD 62 M II-III 1 5 4 11 51 PDD  Cognitive decline and PD (tremor, bradykinesia) - 
TLBD 65 M II 0 5 3 20 45 PD PD (tremor); later at age 57 cognitive decline - 
BLBDa 67 M 0 0 3 / 22 45 PD PD - 
BLBDa 69 M 0-I 0 4 / 18 51 PD PD + 
TLBD 69 M II-III 3 4 5 12 57 PD PD (tremor) + 
TLBD 69 M III 0 3 13 9 60 PDD v MSA PD (bradykines a, shuffling gate) + 
TLBD 70 F III 2 4 / 8 62 PDD PD (tremor); later at age 66 cognitive decline + 
BLBD 71 F III 0 3 / 59 12 PD v ALS PD; later ALS + 
TLBDa 71 M 0 0 4 / 13 58 PD PD; later cognitive decline + 
TLBDb 72 M 0 0 4 8 16 56 PDD PD + 
DLBD 75 M II-III 4 6 4 14 61 PDD PD (tremor) + 
TLBDb 76 M II 1 4 11 30 45 PD PD + 
TLBD 77 M III 2 4 4 23 54 PDD  PD (bradykinesia & tremor), later cognitive decline + 
TLBDa,b 78 M I-II 1 6 / / / PD PD + 
DLBD 78 M II 2 5 8 20 58 PDD PD (bradykinesia); later cognitive decline + 
TLBD 78 M III 0 4 10 12 66 PD PD (tremor, stooped posture) + 
TLBD 78 M III 3 3 6 9 69 PD v ET PD (bradykinesia, balance problems) + 
DLBD 81 F III 3 6 / 16 65 PDD v ET PD (tremor) + 
TLBD 82 M III 0 6 6 11 71 PD  PD (bradykinesia & hypomimia) + 
TLBD 83 M I 0 4 3 15 68 DLB v PDD Cognitive decline; later at age 76 parkinsonism + 
BLBD 84 F III 1 3 5 10 74 PD PD (tremor) + 
BLBDa 84 M I 0 3 / 34 50 PD PD (left arm tremor & rigidity) + 
TLBD 85 M II 1 4 6 30 55 PD PD + 
BLBD 87 M I 3 3 6 11 76 PDD PD (shuffling gait) + depression + confusion + 
DLBD 88 F II-III 4 6 6 23 65 PD PD; later cognitive decline + 
TLBDa,b 90 F III 0 5 32 10 80 PD PD (tremor) + 
TLBD 92 M III 1 4 8 / / PDD N/A + 
All sporadic LBD cases were Caucasian. Abbreviations: PathDX, pathological diagnosis; M, male; F, female; PMI, post-mortem interval; BLBD, brainstem-
predominant Lewy body disease; TLBD, transitional Lewy body disease; DLBD, diffuse Lewy body disease; PD, Parkinson disease; PDD, Parkinson disease 
dementia; DLB, dementia with Lewy bodies; MSA, multiple system atrophy; ALS, amyotrophic lateral sclerosis; ET, essential tremor; /, information unavailable; v, 
indicates versus for clinical differential. 
a Tissue from the substantia nigra was unavailable. 
b Tissue from the amygdala, putamen and nucleus basalis of Meynert were unavailable 
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 Table S3. Characteristics of mutation carrier cohort. 
Gene Mutation PathDx Age Sex 
Braak 
tangle 
stage 
Thal 
amyloid  
phase 
Braak 
PD 
stage 
PMI 
Disease 
duration 
Age 
of 
onset 
Clinical 
Dx 
Reference 
PRKN R275W/+ DLBD 72 M II 0 3 14 / / AD (EPS) 
PRKN R275W/+ AD/TLBD 97 F VI 5 5 14 / / AD 
PRKN R256C/+ TLBD 72 M II-III 3 5 6 / / PDD 
PRKN R256C/+ AD/DLBD 96 F V 5 6 / / / AD 
PRKN L266S/+ TLBD 91 M IV-V 3 4 / / / DLB 
PRKN SNP rs200157467/+ BLBD 78 M I 0 3 20 / / PD 
PRKN Exon 7 deletion/IVS5-1G>A / 75 F / / / / 60 15 PD Cornejo-Olivas MR et al., 2015 [1] 
PINK1 L347P/L347P AD/PDC 85 F IV-V 5 / / 18 67 PDC Steele JC et al., 2015 [2] 
PINK1 c.1252_1488 deletion/c.1488+1G>A / 39 M / / / / 8 31 PD Samaranch L et al., 2010 [3] 
Abbreviations: PathDX, pathological diagnosis; M, male; F, female; PMI, post-mortem interval; BLBD, brainstem-predominant Lewy body disease; TLBD, transitional Lewy body disease; 
DLBD, diffuse Lewy body disease; EPS, extrapyramidal symptoms; PD, Parkinson disease; PDD, Parkinson disease dementia; PDC, parkinsonism-dementia complex; DLB, dementia with 
Lewy bodies; AD, Alzheimer disease; /, information unavailable.   
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